Trust Signals
Key Takeaways
- Tirzepatide is dosed in milligrams, not insulin units. A 2ml vial's "unit" count depends entirely on the concentration, which is not standardized for compounded or research preparations.
- At 5 mg/ml concentration, a 2ml vial contains 10 mg total. At 10 mg/ml, it contains 20 mg. These are two of the most common compounded concentrations but neither is FDA-approved in this format.
- When using a U-100 insulin syringe, 1 unit on the syringe equals 0.01 ml. Divide your mg dose by the vial's mg/ml concentration, then multiply by 100 to get the syringe unit mark to draw to.
- FDA-approved tirzepatide (Mounjaro, Zepbound) comes in single-dose autoinjector pens, not multi-dose 2ml vials. Any 2ml vial is compounded or research-grade, which carries different quality and regulatory considerations.
- A Certificate of Analysis (COA) confirming HPLC-verified peptide content is the only reliable way to trust the labeled concentration on a compounded vial.
Direct Answer: How Many Units in a 2ml Vial of Tirzepatide?
The question cannot be answered with a single number because it depends on concentration. A 2ml vial at 5 mg/ml contains 10 mg total, and at 10 mg/ml it contains 20 mg. The word "units" is borrowed from insulin dosing and does not apply directly to tirzepatide, which is always measured in milligrams.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Why "Units" Confuse People Asking About Tirzepatide
- The Concentration Math: What Is Actually in a 2ml Vial
- Converting mg Doses to Insulin Syringe Units: Step-by-Step
- Evidence Ledger: What the Tirzepatide Data Actually Shows
- What Most Pages Get Wrong About Tirzepatide Vials
- Why Storage and Formulation Change What Is Really in the Vial
- Compounded Vial vs. Approved Pen: Honest Head-to-Head
- Label and COA Literacy: How to Judge What You Have
- Dosing Reference Table by Concentration
- FAQ
- Sources
Why "Units" Confuse People Asking About Tirzepatide?
Most people asking how many units are in a 2ml vial of tirzepatide are using insulin syringes to administer compounded tirzepatide. Insulin syringes in the U-100 format are marked in "units," where 100 units equals 1 ml (or 1 cc). This means 1 unit on a U-100 syringe equals exactly 0.01 ml.
Tirzepatide, however, is not an insulin analog. It is a 39-amino-acid dual GIP/GLP-1 receptor agonist. Its doses are written in milligrams, typically 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per injection, based on the SURPASS clinical trial program that established these doses for Mounjaro and Zepbound (Eli Lilly).
The "units" question emerges because insulin syringes are inexpensive, widely available, and familiar to people self-injecting. They are often used to administer compounded tirzepatide. The syringe marks in units, the dose is prescribed in mg, and the vial is labeled in mg/ml, so bridging three number systems trips people up.
The Concentration Math: What Is Actually in a 2ml Vial?
A 2ml vial is not a standard commercial format for any FDA-approved tirzepatide product. It is a format used by compounding pharmacies and research peptide suppliers. The total content of the vial is simply:
Total mg = Concentration (mg/ml) x Volume (ml)
For a 2ml vial:
| Labeled Concentration | Total mg in 2ml Vial | Notes |
|---|---|---|
| 5 mg/ml | 10 mg | Common compounded concentration |
| 10 mg/ml | 20 mg | Higher-concentration option, less volume per dose |
| 2.5 mg/ml | 5 mg | Lower concentration, seen in some preparations |
| Variable / unlabeled | Unknown | Do not use without COA confirmation |
Converting mg Doses to Insulin Syringe Units: Step-by-Step
The formula is straightforward once you know the vial concentration:
- Identify the vial concentration in mg/ml (from the label and COA).
- Identify the target dose in mg (from a prescribing clinician).
- Divide dose (mg) by concentration (mg/ml) to get volume in ml.
- Multiply ml by 100 to get the number of units to draw on a U-100 insulin syringe.
Formula: Units on U-100 syringe = (Dose in mg / Concentration in mg/ml) x 100
| Target Dose (mg) | Vial at 5 mg/ml: Draw to (units) | Vial at 10 mg/ml: Draw to (units) |
|---|---|---|
| 2.5 mg | 50 units | 25 units |
| 5 mg | 100 units (full 1ml syringe) | 50 units |
| 7.5 mg | 150 units (1.5ml, requires larger syringe) | 75 units |
| 10 mg | 200 units (requires 2ml syringe) | 100 units |
| 12.5 mg | 250 units (requires 2.5ml syringe) | 125 units |
| 15 mg | 300 units (requires 3ml syringe) | 150 units |
At 5 mg/ml concentration, doses above 5 mg exceed the capacity of a standard 1ml insulin syringe. A 10 mg/ml concentration keeps all standard tirzepatide doses within a 1.5ml draw volume, which is one practical reason higher concentrations are used.
Evidence Ledger: What the Tirzepatide Data Actually Shows
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Tirzepatide at 5 to 15 mg doses reduces body weight significantly in people with obesity | Human RCT (SURMOUNT-1, n=2,539) | Positive, dose-dependent | High |
| Tirzepatide reduces HbA1c in type 2 diabetes at 5 to 15 mg doses | Human RCT (SURPASS program, multiple trials) | Positive | High |
| Compounded tirzepatide vials deliver the labeled dose reliably | No published RCT; regulatory inspection data only | Variable/uncertain | Very Low |
| The pharmacokinetics of compounded tirzepatide match the approved product | No published human PK study for compounded versions | Unknown | Very Low |
| Tirzepatide acts as a dual GIP/GLP-1 receptor agonist | In vitro receptor binding studies, confirmed in FDA review | Established mechanism | High |
| Dose titration from 2.5 mg reduces GI adverse events | Human RCT protocol design (SURPASS/SURMOUNT) | Positive for tolerability | Moderate |
The entire human evidence base for tirzepatide efficacy and safety was built using the pharmaceutical-grade autoinjector pen product, not compounded vials. Extrapolating those findings to a compounded 2ml vial assumes equivalent bioavailability and dose accuracy, which has not been demonstrated in published studies.
What Most Pages Get Wrong About Tirzepatide Vials
Most guides answer the "units" question by picking a single concentration and presenting it as universal. That is the wrong approach because:
1. No standard exists for compounded vial concentration. Compounding pharmacies are not required to use a uniform concentration. A 2ml vial from one pharmacy may be 5 mg/ml; from another it may be 10 mg/ml. Drawing the same "50 units" from both vials delivers doses that differ by a factor of two. This is not a minor dosing nuance. It is a clinically significant error source.
2. "Units" from an insulin syringe is a volume measure disguised as a dose measure. When you draw 50 units on a U-100 syringe, you are drawing 0.5 ml. How much tirzepatide that is depends on concentration. Guides that say "draw X units for a Y mg dose" are embedding a hidden concentration assumption that may be wrong for your vial.
3. Lyophilized powder vials add a reconstitution variable. Some compounded tirzepatide arrives as a powder. The total mg content is fixed, but the concentration depends on how much bacteriostatic water you add. If the instruction says "add 2ml of bacteriostatic water to a 10mg powder vial," the resulting concentration is 5 mg/ml. If someone adds 1ml, the concentration doubles. Most guides do not address this variable.
4. The FDA shortage and compounding status has changed. The FDA determined in early 2025 that tirzepatide is no longer in shortage, which affects the legal status of compounded tirzepatide under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Pages written before that determination may present outdated regulatory context.
Why Storage and Formulation Change What Is Really in the Vial
The number you calculate from concentration math assumes the peptide is fully intact and at the stated potency. Tirzepatide is a 39-amino-acid synthetic peptide. Peptides are susceptible to specific degradation pathways that matter for dosing accuracy:
Hydrolysis: Peptide bonds break in aqueous solution over time. The rate accelerates with temperature. This is why reconstituted peptide solutions should be stored at 2 to 8 degrees Celsius and used within the timeframe specified by the compounder's stability testing. A vial left at room temperature for extended periods likely contains less active tirzepatide than the label states, without any visible change in the solution.
Oxidation: Tirzepatide contains amino acids susceptible to oxidation (methionine residues, if present in the sequence, are a classic oxidation site in GLP-1 class peptides). Exposure to light, oxygen, or repeated needle punctures that introduce air can accelerate oxidative degradation. This is why multi-dose vials should use bacteriostatic water (which extends microbial stability) and be stored away from light.
Aggregation: At higher concentrations or with repeated temperature fluctuation, peptide molecules can aggregate. Aggregation reduces bioavailability and can, in principle, generate immunogenic species. Visible cloudiness or particulates are a sign of aggregation severe enough to see. Subclinical aggregation is not visible.
Practical implication: If your vial is old, has experienced temperature excursions, or was not stored properly, the effective dose per unit volume is lower than the label states. There is no home test for this. The only protection is proper cold-chain handling and using product within the stability window validated by the manufacturer or compounding pharmacy.
Compounded 2ml Vial vs. FDA-Approved Autoinjector Pen: Honest Comparison
| Factor | Compounded 2ml Vial | FDA-Approved Pen (Mounjaro/Zepbound) |
|---|---|---|
| Dose accuracy | Depends on concentration accuracy (COA-dependent), user drawing technique, and reconstitution if applicable | Fixed, pre-filled, pen-verified by manufacturer QC |
| Regulatory oversight | State board of pharmacy and 503A/B standards; no FDA batch approval | Full FDA NDA/BLA manufacturing oversight |
| Evidence base | Clinical evidence does not exist for compounded version specifically | SURPASS (type 2 diabetes) and SURMOUNT (obesity) RCT programs |
| Cost | Often lower per mg, but varies widely | High list price; insurance coverage variable |
| Convenience | Requires syringe, needle, aseptic technique, calculation | Pre-filled, single-use pen with fixed dose |
| Sterility assurance | Depends on compounder's testing and user technique | Sterility validated at manufacturing |
| Legal status (US, 2025 onward) | Restricted following FDA shortage resolution; clinical need pathway remains | Fully legal and indicated |
| Shelf life certainty | Stability data varies; often limited to compounder's internal testing | Published expiration dating with validated stability data |
The compounded vial loses on every quality and evidence dimension. The only scenario where it competes is access and cost, and both of those advantages narrowed after the FDA shortage resolution. A skeptical clinician would not treat compounded tirzepatide as equivalent to the approved product for the purposes of applying published efficacy or safety data.
Label and COA Literacy: How to Judge What You Have
When evaluating a 2ml tirzepatide vial, ask for and review these specific items:
On the vial label, confirm:
- Concentration stated in mg/ml (not just total mg)
- Lot number traceable to a COA
- Expiration or use-by date
- Storage conditions stated (typically refrigerate at 2 to 8 degrees C)
- Compounding pharmacy name and contact information
- Whether the vial is a liquid solution or lyophilized powder requiring reconstitution
On the COA, look for:
- Identity confirmation: HPLC or mass spectrometry confirmation that the peptide is tirzepatide and not a related analog
- Peptide purity: expressed as a percentage; research-grade preparations typically target above 95%, pharmaceutical compounding typically targets higher
- Measured concentration: the COA should state the actual measured mg/ml, not just confirm the label claim
- Endotoxin testing: critical for injectable preparations; LAL (limulus amebocyte lysate) testing is standard
- Sterility testing: USP or equivalent method
What a degraded vial looks like: Solution should be clear and colorless to faintly yellow. Cloudiness, visible particles, or yellow-to-brown discoloration indicate degradation or contamination. Discard immediately. Note that potency loss can occur without visible change, so proper storage from the start is the only reliable protection.
Dosing Reference Table by Concentration
These calculations assume a U-100 insulin syringe and verified vial concentration. Verify your dose with a prescribing clinician before use.
| Dose (mg) | 5 mg/ml: Volume (ml) | 5 mg/ml: U-100 Units | 10 mg/ml: Volume (ml) | 10 mg/ml: U-100 Units |
|---|---|---|---|---|
| 2.5 | 0.50 ml | 50 | 0.25 ml | 25 |
| 5.0 | 1.00 ml | 100 | 0.50 ml | 50 |
| 7.5 | 1.50 ml | 150 | 0.75 ml | 75 |
| 10.0 | 2.00 ml | 200 | 1.00 ml | 100 |
| 12.5 | 2.50 ml | 250 | 1.25 ml | 125 |
| 15.0 | 3.00 ml | 300 | 1.50 ml | 150 |
Bolded takeaway: At 5 mg/ml, any dose above 5 mg requires a syringe larger than 1ml. A standard U-100 insulin syringe holds only 1ml (100 units). Using a 5 mg/ml vial for doses of 7.5 mg or higher requires a 2ml or 3ml syringe, which changes both the syringe markings and the precision available.
FAQ
How many units in a 2ml vial of tirzepatide?
The answer depends entirely on the concentration of the reconstituted or compounded vial. A 2ml vial is not a standard commercial format for tirzepatide. At a common research compounding concentration of 5 mg/ml, a 2ml vial contains 10 mg total. At 10 mg/ml it contains 20 mg. "Units" in the insulin-syringe sense are not the correct measurement for tirzepatide; doses are measured in milligrams and drawn in volume (ml or cc).
Why do people ask about "units" for tirzepatide when the dose is in mg?
Most people asking about units are using insulin syringes, which are marked in "units" rather than ml. An insulin syringe labeled U-100 delivers 1 unit = 0.01 ml. Knowing this conversion lets you read an insulin syringe correctly for a tirzepatide dose expressed in mg.
How do I convert a tirzepatide mg dose to units on an insulin syringe?
Divide your target dose in mg by the vial concentration in mg/ml to get the volume in ml. Then multiply by 100 to get U-100 insulin syringe units. Example: 2.5 mg dose, 5 mg/ml vial: 2.5 divided by 5 = 0.5 ml = 50 units on a U-100 syringe.
What concentrations do 2ml tirzepatide vials commonly come in?
Compounded tirzepatide vials are not standardized. Common concentrations seen in research-grade preparations include 5 mg/ml and 10 mg/ml, yielding 10 mg or 20 mg per 2ml vial respectively. Always verify the concentration label and COA before drawing any dose.
What is the standard commercial tirzepatide vial format?
FDA-approved Mounjaro and Zepbound are supplied as single-dose autoinjector pens, not multi-dose vials. Each pen delivers a fixed dose (2.5, 5, 7.5, 10, 12.5, or 15 mg). There is no standard 2ml vial in the commercial approved product line.
How do I check if my vial concentration is correct?
Request the Certificate of Analysis (COA) from the supplier. The COA should confirm identity by HPLC, state the measured peptide content in mg, and ideally confirm sterility and endotoxin levels. The label concentration must match the COA measured concentration within a tight tolerance.
What does degraded tirzepatide look like in a vial?
Visible signs of degradation include cloudiness, visible particulates, or a yellow-brown discoloration in a solution that should be clear and colorless to pale yellow. Any of these signs warrant discarding the vial. Loss of potency without visible change is also possible, which is why cold storage and proper reconstitution matter.
How long does a reconstituted 2ml tirzepatide vial remain stable?
Stability data specific to compounded tirzepatide formulations is limited. General peptide stability guidelines suggest refrigerated storage (2 to 8 degrees Celsius), minimizing freeze-thaw cycles, and use within a period that varies by formulation. Consult the compounding pharmacy's COA or stability testing report for the specific product.
Is a 2ml vial of tirzepatide the same as a lyophilized powder vial?
Not necessarily. Some compounded tirzepatide arrives as a lyophilized (freeze-dried) powder that requires reconstitution with bacteriostatic water. Others arrive as a pre-mixed liquid solution. The 2ml label may refer to either the final liquid volume or the reconstitution target volume. Check the product format before drawing a dose.
What is the key safety risk when drawing tirzepatide from a multi-dose vial?
The main risks are dosing errors from concentration confusion, contamination from poor aseptic technique, and using a degraded product. Because 2ml vials are not a standardized FDA-approved format, concentration variability across suppliers is a real concern. A 2x error in concentration means a 2x error in dose.
How does compounded tirzepatide compare to FDA-approved Mounjaro or Zepbound?
FDA-approved Mounjaro and Zepbound have been through rigorous clinical trials establishing safety and efficacy with verified doses. Compounded tirzepatide lacks that batch-level regulatory oversight, meaning concentration, purity, and sterility can vary. The clinical evidence for tirzepatide's effects comes from the approved drug, not from compounded versions.
Sources
- Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. U.S. Food and Drug Administration. Available at: FDA.gov/drugs. Revised 2023.
- Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. U.S. Food and Drug Administration. Available at: FDA.gov/drugs. Revised 2023.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial, n=2,539)
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-515. (SURPASS-2)
- U.S. Food and Drug Administration. Drug Shortages: Tirzepatide. FDA Drug Shortages Database. Updated 2025. Available at: accessdata.fda.gov/scripts/drugshortages.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Available at: FDA.gov/drugs/human-drug-compounding. Reviewed 2024.
- U.S. Pharmacopeial Convention. USP General Chapter 797: Pharmaceutical Compounding: Sterile Preparations. USP-NF. Revised 2023.
- U.S. Food and Drug Administration. FDA Alerts Health Care Providers and Compounders About the Risks of Compounded Tirzepatide Products. FDA Safety Alert. 2024.